BioCentury
ARTICLE | Finance

Ready to launch

A record 59 NME approvals in 2018 means investors will focus on launches in 2019

January 5, 2019 2:49 AM UTC

The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record year for NME approvals by FDA.

Several investors expect “shorting the launch” to be an ongoing theme, particularly among small and mid-cap biotechs looking to launch products independently. ...